Myeloma Therapy: Pursuing the Plasma Cell

ISBN-13: 9781934115824 / Angielski / Twarda / 2008 / 670 str.

Sagar Lonial

Opis

Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care.

Recenzje

From the reviews:

"The book Myeloma Therapy: Pursuing the Plasma Cell, edited by Sagar Lonial, arrives just in time. ... a comprehensive, updated review of all the problems concerning myeloma. The authors are among the world's top scientific leaders in this field ... . Consultation and systematic reading are interesting, useful, and very agreeable. It cannot be lacking in the library of the hematologists and oncologists taking care of myeloma patients, and it's also a worthwhile volume for scientists involved in preclinical research." (Sergio Storti, Laboratory Hematology, Vol. 15 (34), 2009)

"Myeloma therapy by Sagar Lonial deals with various aspects of the plasma cell disorders and multiple myeloma in particular. ... this is a goldmine of information written in a style that is accessible to the biochemically interested clinician. ... is highly recommended to the advanced reader in this field. It is a reference work on both clinical and biological aspects of multiple myeloma and should be part of the libraries of hospitals for physicians who are professionally frequently involved with the treatment of this disease." (F. Offner, Acta Clinica Belgica, Vol. 65 (3), 2010)

Spis treści

Section 1: Biologic Considerations and Myeloma Staging and Myeloma L.T. Heffner MD Epidemiology of Multiple Myeloma A.A Langston MD and Dixil Francis Basic Biology of Plasma Cell Dyscrasias Kenneth Anderson MD, DFCI and Marc S. Raab Biology Based Classification and Staging of Multiple Myeloma Peter Leif Bergsagel MD and Wee Joo Chng, MD The importance of FISH and Cytogenetics R. Fonseca MD, Esteban Braggio and Michael Sebag Section 2: Historical and Cytotoxic Agent based Therapies for Myeloma Role of Autologous Stem Cell Transplantation In Multiple Myeloma J.L. Harrouseau, MD Maintenance Therapy In Multiple Myeloma Jonathan L. Kaufman MD, Ronald Mihelic PharmD, and Sagar Lonial, MD Therapy for Patients not Eligible for Autologous Transplant Antonio Palumbo, MD and Sara Bringhen, MD Current Role of Anthracyclines in the Treatment of Multiple Myelma, A. Chanan-Khan, MD and Sikander Ailawadhi Section 3: Immune Based Therapies Allogeneic Transplantation for Multiple Myeloma Edmund K. Waller MD, PhD Fengrong Wang, MD Immunobiology and Immunotherapy of Multiple Myeloma Madhav Dhodapkar MD Antibody and other Immune based therapies for Myeloma N Munshi MD, DFCI Section 4: Existing novel agents Thalidomide In Relapsed Multiple Myeloma Patients Ashraf Badros MD Thalidomide: Induction Therapy S. Vincent Rajkumar MD and Francis K. Baudi, MD The Role of Bortezomib In the Treatment of Relapsed and Refractory Multiple Myeloma Paul G. Richardson MD, DFCI, Constantine S. Mitsiades, Robert Schlossman, Irene Ghobrial, Nikhil C. Munshi and Kenneth C. Anderson Bortezomib As Induction Therapy In Multiple Myeloma Patients J San Miguel MD,PhD and M.V. Mateos, MD, PhD Lenalidomide In Relapsed and Refractory Multiple Myeloma Donna M. Weber MD, Sheeba K. Thomas MD, Tiffany A. Richards, MS, ANP, AOCNP Lenalidomide (Revlimid®) For Initial Therapy of Newly Diagnosed Multiple Myeloma Shaji Kumar MD Section 5: Current and Future Targets The Role of Heat Shock Protein 90 As A Therapeutic Target for Multiple Myeloma Constantine Mitsiades MD, DFCI, Teru Hideshima, Nikhil C. Munshi, Paul G. Richardson and Kenneth C. Anderson The P13 Kinase/AKT Pathway As A therapeutic Target for Multiple Myeloma Donald Harvey, PharmD, Jeanine Silberman, MD and Sagar Lonial MD The Mammalian Target of Rapamycin (mTOR) and Multiple Myeloma Patrick Frost, PhD Alan Lichtenstein, MD CDK Inhibitors In Multiple Myeloma Yun Dai and Steven Grant MD, MCV Fibroblast growth factor receptor 3 (FGFR3) and Multiple Myeloma (MM) Victor Hugo Jimenez-Zepeda, MD and Keith Stewart MD Histone Deacetylase Inhibitors In Multiple Myeloma Teru Hideshima MD, PhD, DFCI Death Receptors In Multiple Myeloma and Therapeutic Opportunities, F. Mollinedo, PhD Proteasome Inhibitors as Therapy in Multiple Myeloma Dharminder Chauhan PhD, Ajita Singh, PhD and Kenneth Anderson, MD Section 6: Supportive Care Pathophysiology of Bone Disease in Multiple Myeloma Tomer M. Mark, MD and Roger N. Pearse MD, PhD Anemia and Erythropoeitic Growth Factors in Multiple Myeloma N Raje MD, DFCI Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Acute Painful Pathologic and Non-Pathologic Fractures Sandra Narayanan, MD and Frank Tong MD The Role of Anatomic and

Blurb

Therapeutic options for patients with myeloma have radically changed over the past ten years. Myeloma Therapy: Pursuing the Plasma Cell provides updated various treatment options for patients with myeloma, with focus on the emerging and speculative aspects of myeloma therapy. Written by clearly acknowledged leaders in the field of myeloma therapy and research, Myeloma Therapy: Pursuing the Plasma Cell presents significant material on the biology and potential agents used to address specific signaling pathways, all of which are critical to myeloma biology and therapy. State of the art information from many of the leaders in the plasma cell disorders world includes disease pathogenesis and biology, chemotherapy based approaches, immune based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders. Myeloma Therapy: Pursuing the Plasma Cell is a comprehensive collection and tremendous source in this time of rapid change in clinical and preclinical disease knowledge.